ArticleG3 (Bethesda, Md.)2019
Validation and Characterization of Maize Multiple Disease Resistance QTL.
Article in G3 (Bethesda, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Reply: neutral transcriptome rewiring promotes quantitative disease resistance evolvability at the species level.The Plant cell · 2026Article
- Identification and fine-mapping ofMolecular breeding : new strategies in plant improvement · 2025Article
- A maize near-isogenic line population designed for gene discovery and characterization of allelic effects.The Plant journal : for cell and molecular biology · 2025Article
- Identification of gray leaf spot-resistant donor lines in tropical maize germplasm and their agronomic performance under artificial inoculation.Frontiers in plant science · 2025Article
- Insights into maydis leaf blight resistance in maize: a comprehensive genome-wide association study in sub-tropics of India.BMC genomics · 2024Article
- Identification of loci conferring resistance to 4 foliar diseases of maize.G3 (Bethesda, Md.) · 2024Article
- Recent advances in the population biology and management of maize foliar fungal pathogensFrontiers in plant science · 2024Review
- Combination of linkage and association mapping with genomic prediction to infer QTL regions associated with gray leaf spot and northern corn leaf blight resistance in tropical maize.Frontiers in genetics · 2023Article
- Bioinformatics in Plant Breeding and Research on Disease Resistance.Plants (Basel, Switzerland) · 2022Review
- Quantitative trait loci mapping for free amino acid content using an albino population and SNP markers provides insight into the genetic improvement of tea plants.Horticulture research · 2022Article
- Transgressive resistance to Heterodera glycines in chromosome segment substitution lines derived from susceptible soybean parents.The plant genome · 2021Article
- Genome-wide association studies in tropical maize germplasm reveal novel and known genomic regions for resistance to Northern corn leaf blight.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Southern Leaf Blight, Northern Leaf Blight, and Gray Leaf Spot, caused by ascomycete fungi, are among the most important foliar diseases of maize worldwide. Previously, disease resistance quantitative trait loci (QTL) for all three diseases were identified in a connected set of chromosome segment substitution line (CSSL) populations designed for the identification of disease resistance QTL. Some QTL for different diseases co-localized, indicating the presence of multiple disease resistance (MDR) QTL. The goal of this study was to perform an independent test of several of the MDR QTL identified to confirm their existence and derive a more precise estimate of allele additive and dominance effects. Twelve F
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.